Clear Harbor Asset Management LLC purchased a new position in shares of Crispr Therapeutics AG (NASDAQ:CRSP) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 730 shares of the company’s stock, valued at approximately $44,000.
Other large investors have also recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Crispr Therapeutics by 13.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,870 shares of the company’s stock valued at $118,000 after acquiring an additional 343 shares during the last quarter. Traynor Capital Management Inc. boosted its position in Crispr Therapeutics by 5.8% during the 3rd quarter. Traynor Capital Management Inc. now owns 6,845 shares of the company’s stock worth $280,000 after acquiring an additional 375 shares during the last quarter. Commonwealth Equity Services LLC boosted its position in Crispr Therapeutics by 2.2% during the 3rd quarter. Commonwealth Equity Services LLC now owns 18,201 shares of the company’s stock worth $746,000 after acquiring an additional 386 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA acquired a new position in Crispr Therapeutics during the 4th quarter worth approximately $26,000. Finally, Webster Bank N. A. acquired a new position in Crispr Therapeutics during the 4th quarter worth approximately $26,000. 50.01% of the stock is owned by hedge funds and other institutional investors.
In related news, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the sale, the president now owns 33,618 shares in the company, valued at $2,353,260. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction on Tuesday, November 12th. The stock was sold at an average price of $55.00, for a total value of $412,500.00. Following the sale, the director now owns 7,500 shares of the company’s stock, valued at approximately $412,500. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,618 shares of company stock valued at $3,230,760. Corporate insiders own 21.40% of the company’s stock.
Crispr Therapeutics stock opened at $52.32 on Friday. The firm has a market cap of $3.00 billion, a P/E ratio of -113.74 and a beta of 3.25. Crispr Therapeutics AG has a one year low of $29.92 and a one year high of $74.00. The stock’s 50 day moving average is $59.31 and its 200 day moving average is $52.83. The company has a debt-to-equity ratio of 0.06, a current ratio of 8.32 and a quick ratio of 8.32.
A number of research firms have weighed in on CRSP. TheStreet raised Crispr Therapeutics from a “d” rating to a “c” rating in a research report on Monday, October 28th. Roth Capital raised their price target on Crispr Therapeutics from $65.00 to $100.00 in a report on Tuesday, November 19th. Wells Fargo & Co reiterated a “buy” rating on shares of Crispr Therapeutics in a research report on Friday, December 6th. BidaskClub cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, January 23rd. Finally, ValuEngine cut Crispr Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, January 3rd. Three analysts have rated the stock with a sell rating, one has issued a hold rating and twelve have assigned a buy rating to the stock. Crispr Therapeutics presently has an average rating of “Buy” and a consensus target price of $75.95.
Crispr Therapeutics Profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Article: Why does a company issue an IPO?
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.